CyDex Pharmaceuticals Receives a Key U.S. Patent for Composition of Matter and Process of Manufacturing High-Purity Captisol(R)
1/5/2010 11:39:32 AM
LENEXA, Kan.--(BUSINESS WIRE)--CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled “Sulfoalkyl Ether Cyclodextrin Compositions.” This patent, along with other previously issued technology patents, will provide broad protection for CyDex’s Captisol® technology until 2029. The most recent of these previously issued patents – for a new Captisol that flows better, dissolves faster, and packs more densely than previous morphologies – was announced on December 9, 2009.
comments powered by